What is Wellpartner?
Founded in 2000, Wellpartner operates at the intersection of pharmacy services and healthcare technology. The company provides comprehensive management solutions for the 340B Drug Program, a critical framework for healthcare organizations seeking to preserve resources while expanding patient access. By integrating retail pharmacy expertise with advanced software, Wellpartner enables covered entities to navigate complex regulatory environments, ensure program compliance, and improve specialty network access. Their market position is defined by a focus on operational efficiency and the delivery of seamless, technology-driven services that address the unique challenges of the 340B landscape.
How much funding has Wellpartner raised?
Wellpartner has raised a total of $37.6M across 3 funding rounds:
Series B
$14M
Series C
$7.5M
Series D
$16.1M
Series B (2005): $14M with participation from Scorpion Capital Partners
Series C (2007): $7.5M led by Integra Ventures, 3i Group, Montlake Capital, Greenwoods Asset Management, and Mediphase Venture Partners
Series D (2008): $16.1M supported by Greenwood Management, Integra Ventures, 3i Group, Montlake Capital, and Mediphase Venture Partners
Key Investors in Wellpartner
Mediphase Venture Partners
A venture capital firm focusing on health care and life sciences, known for taking active board roles to promote rapid growth in biopharmaceutical technology.
3i Group
An international investment company specializing in private equity and infrastructure, with a strong focus on mid-market companies across North America and Europe.
Montlake Capital
An investment firm established in 1999 that provides flexible, long-term growth support for businesses across the Pacific Northwest, spanning B2B and technology sectors.
What's next for Wellpartner?
Looking ahead, Wellpartner is positioned to leverage its enterprise-level funding to further penetrate the healthcare services market. The strategic focus remains on enhancing the scalability of its compliance management tools and expanding its specialty pharmacy network. As the regulatory environment for the 340B Drug Program continues to evolve, Wellpartner's emphasis on data-driven claims capture and operational excellence will likely serve as a primary differentiator. The company is expected to continue its trajectory of growth by deepening its integration with healthcare providers and investing in next-generation pharmacy technology to maintain its competitive edge in the sector.
See full Wellpartner company page
